News | May 26, 2025
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The company expects meaningful revenue contribution from this long-term agreement
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Subscribe To Our Newsletter & Stay Updated
